Skip to main content
Clinical Trials/NCT05999721
NCT05999721
Recruiting
Not Applicable

The Effect of Superficial Parasternal Intercostal Plane Block on Pulmonary Function Tests After Cardiac Surgery (PIPACS Trial): a Prospective, Double-blind, Randomised Controlled Trial.

Shai Fein2 sites in 1 country100 target enrollmentJanuary 25, 2025

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Postoperative Pain
Sponsor
Shai Fein
Enrollment
100
Locations
2
Primary Endpoint
Percentage Change in Forced Expiratory Volume in the First Second (FEV1)
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

In adult patients undergoing cardiac surgery, does adding an sPIP block to standard care compared to standard care alone result in a smaller decrease in PFTs?

Detailed Description

Postoperative pulmonary complications are a significant concern after cardiac surgery, with post-sternotomy pain contributing to impaired pulmonary function and increased risk of these complications. Parasternal intercostal plane blocks have recently emerged as a promising analgesic option for cardiac surgery, but their impact on pulmonary function tests (PFTs) has yet to be evaluated. This prospective, single-center, double-blind, randomized controlled trial will recruit 100 adult patients undergoing elective cardiac surgery. Baseline pulmonary function, including FEV1, FVC, and PEF, will be measured preoperatively and reassessed on the first postoperative day to evaluate the primary outcome: percentage change in PFT values. Secondary outcomes include pain scores, opioid consumption, incidence of postoperative pulmonary complications during hospitalization, duration of cardiothoracic intensive care and hospital stays, and 30-day mortality. This study aims to determine whether adding a superficial parasternal intercostal plane (sPIP) block to standard care better preserves pulmonary function in adult patients undergoing elective cardiac surgery.

Registry
clinicaltrials.gov
Start Date
January 25, 2025
End Date
January 1, 2026
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
Shai Fein
Responsible Party
Sponsor Investigator
Principal Investigator

Shai Fein

Principal Investigator, Head of Department, Department of Anesthesia, Beilinson Hospital, Rabin Medical Centre, Petach Tikva, Israel.

Rabin Medical Center

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Percentage Change in Forced Expiratory Volume in the First Second (FEV1)

Time Frame: Baseline (preoperative) and first postoperative day

Percentage change in FEV1 (measured in litres) from baseline to the first postoperative day.

Percentage Change in Forced Vital Capacity (FVC)

Time Frame: Baseline (preoperative) and first postoperative day

Percentage change in FVC (measured in litres) from baseline to the first postoperative day.

Percentage Change in Peak Expiratory Flow (PEF)

Time Frame: Baseline (preoperative) and first postoperative day

Percentage change in PEF (measured in litres per second) from baseline to the first postoperative day.

Secondary Outcomes

  • Pain scores, measured by Numeric Rating Scale (NRS)(0-8 hours, 8-16 hours, 16-24 hours, 24-48 hours, and 48-72 hours postoperatively)
  • Opioid consumption, measured in Morphine Milligram Equivalents (MME)(0-8 hours, 8-16 hours, 16-24 hours, 24-48 hours, and 48-72 hours postoperatively)
  • Postoperative pulmonary complication, based on the European perioperative clinical outcome (EPCO) criteria(30 days)
  • Length of stay(30 days)
  • Mortality(30 days)

Study Sites (2)

Loading locations...

Similar Trials